TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

02 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

20 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

26 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

25 Feb 2025 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

24 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

20 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

03 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 Sep 2024 18:00:00 By Nasdaq GlobeNewswire

Terns Announces Pricing of Upsized $150.15 Million Public Offering

10 Sep 2024 21:50:00 By Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

09 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

09 Sep 2024 06:05:00 By Nasdaq GlobeNewswire